BACKGROUND: Serum bactericidal antibody titres that correlate with protection against invasive meningococcal disease have been characterised. However, titres that are associated with protection against acquisition of pharyngeal carriage of Neisseria meningitidis are not known. METHODS: Sera were obtained from the members of a household in seven countries of the African meningitis belt in which a pharyngeal carrier of N. meningitidis had been identified during a cross-sectional survey. Serum bactericidal antibody titres at baseline were compared between individuals in the household of the carrier who became a carrier of a meningococcus of the same genogroup during six months of subsequent follow-up and household members who did not become a ...
SummaryObjectivesNeisseria meningitidis is the major cause of seasonal meningitis epidemics in the A...
SummaryBackgroundInformation on transmission of meningococcal infection in the African meningitis be...
Invasive meningococcal disease (IMD) affects approximately 1.2 million people worldwide annually. Pr...
BACKGROUND: Serum bactericidal antibody titres that correlate with protection against invasive menin...
Serum bactericidal antibody titres that correlate with protection against invasive meningococcal dis...
OBJECTIVES: Neisseria meningitidis, together with the non-pathogenic Neisseria species (NPNs), are m...
OBJECTIVE: To review the findings of studies of pharyngeal carriage of Neisseria meningitidis and re...
SummaryObjectivesNeisseria meningitidis, together with the non-pathogenic Neisseria species (NPNs), ...
Objectives: Carriers of Neisseria meningitidis are a key source of transmission. In the African meni...
A meningococcal serogroup A polysaccharide/tetanus toxoid conjugate vaccine (PsA-TT) (MenAfriVac(™) ...
BACKGROUND: Information on transmission of meningococcal infection in the African meningitis belt is...
Information on transmission of meningococcal infection in the African meningitis belt is scarce. We ...
BACKGROUND: Study of meningococcal carriage is essential to understanding the epidemiology of Neisse...
In the African “meningitis belt,” outbreaks of meningococcal meningitis occur in cycles, representin...
After an epidemic of serogroup A meningococcal meningitis in northern Ghana, a gradual disappearance...
SummaryObjectivesNeisseria meningitidis is the major cause of seasonal meningitis epidemics in the A...
SummaryBackgroundInformation on transmission of meningococcal infection in the African meningitis be...
Invasive meningococcal disease (IMD) affects approximately 1.2 million people worldwide annually. Pr...
BACKGROUND: Serum bactericidal antibody titres that correlate with protection against invasive menin...
Serum bactericidal antibody titres that correlate with protection against invasive meningococcal dis...
OBJECTIVES: Neisseria meningitidis, together with the non-pathogenic Neisseria species (NPNs), are m...
OBJECTIVE: To review the findings of studies of pharyngeal carriage of Neisseria meningitidis and re...
SummaryObjectivesNeisseria meningitidis, together with the non-pathogenic Neisseria species (NPNs), ...
Objectives: Carriers of Neisseria meningitidis are a key source of transmission. In the African meni...
A meningococcal serogroup A polysaccharide/tetanus toxoid conjugate vaccine (PsA-TT) (MenAfriVac(™) ...
BACKGROUND: Information on transmission of meningococcal infection in the African meningitis belt is...
Information on transmission of meningococcal infection in the African meningitis belt is scarce. We ...
BACKGROUND: Study of meningococcal carriage is essential to understanding the epidemiology of Neisse...
In the African “meningitis belt,” outbreaks of meningococcal meningitis occur in cycles, representin...
After an epidemic of serogroup A meningococcal meningitis in northern Ghana, a gradual disappearance...
SummaryObjectivesNeisseria meningitidis is the major cause of seasonal meningitis epidemics in the A...
SummaryBackgroundInformation on transmission of meningococcal infection in the African meningitis be...
Invasive meningococcal disease (IMD) affects approximately 1.2 million people worldwide annually. Pr...